Kamada Ltd. (KMDA) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. lifted its stake in shares of Kamada Ltd. (NASDAQ:KMDA) by 6.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 468,390 shares of the biotechnology company’s stock after acquiring an additional 28,382 shares during the period. Vanguard Group Inc. owned approximately 1.30% of Kamada worth $2,810,000 as of its most recent SEC filing.

Separately, Renaissance Technologies LLC lifted its holdings in shares of Kamada by 16.7% during the 1st quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock worth $1,801,000 after acquiring an additional 37,800 shares during the last quarter. Institutional investors and hedge funds own 6.31% of the company’s stock.

Shares of Kamada Ltd. (KMDA) opened at $4.55 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.71 and a quick ratio of 2.73. Kamada Ltd. has a one year low of $3.75 and a one year high of $8.61.

A number of analysts have recently issued reports on KMDA shares. Jefferies Group reaffirmed a “buy” rating and set a $7.00 price objective on shares of Kamada in a report on Thursday, October 12th. Zacks Investment Research raised shares of Kamada from a “sell” rating to a “hold” rating in a report on Wednesday, October 25th. Finally, ValuEngine downgraded shares of Kamada from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Two investment analysts have rated the stock with a sell rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $8.50.

ILLEGAL ACTIVITY NOTICE: “Kamada Ltd. (KMDA) Shares Bought by Vanguard Group Inc.” was reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://transcriptdaily.com/2017/12/06/kamada-ltd-kmda-shares-bought-by-vanguard-group-inc.html.

Kamada Profile

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Want to see what other hedge funds are holding KMDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kamada Ltd. (NASDAQ:KMDA).

Institutional Ownership by Quarter for Kamada (NASDAQ:KMDA)

Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply